The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Center experience: immunotherapy in Southampton
CAR T-cell therapy for lung cancer?
Future direction for cancer immunotherapy
SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations